SAN DIEGO--(BUSINESS WIRE)--Ardea Biosciences, Inc. (Nasdaq:RDEA), announced today that the Company will host an Investor and Analyst Event on Monday, April 20, 2009 from 4:30 p.m. to 7:00 p.m. Eastern Daylight Time in New York City. Ardea management will present results from its Phase 1 studies of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout, and Phase 2a study of RDEA806, RDEA594’s prodrug, in patients with gout. Plans for the Phase 2 development program with RDEA594, scheduled to start in the second quarter of 2009, will also be presented.
